SCHEDULE: Cormorant Asset Management Discloses 6.1% MoonLake Stake

Cormorant Asset Management, LP and Bihua Chen have reported a 6.10% beneficial ownership stake in MoonLake Immunotherapeutics' Class A ordinary shares.

Summary

• Cormorant Asset Management, LP and Bihua Chen have filed a Schedule 13G, disclosing beneficial ownership of MoonLake Immunotherapeutics' Class A ordinary shares.
• The reporting persons collectively own 4,355,433 Class A ordinary shares.
• This represents 6.10% of the total Class A ordinary shares outstanding.
• The ownership percentage is calculated based on 71,373,579 Class A Ordinary Shares outstanding following a public offering that closed around November 6, 2025.
• Cormorant Asset Management, LP is an investment adviser, and Bihua Chen is an individual associated with the firm.
• The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a substantial passive investment by a specialized fund like Cormorant Asset Management suggests a belief in MoonLake Immunotherapeutics' long-term value proposition without immediate intentions to influence control.

Positives

• A significant institutional investor, Cormorant Asset Management, LP, has taken a substantial stake (6.10%) in MoonLake Immunotherapeutics, potentially signaling confidence in the company's future prospects.
• The filing under Rule 13d-1(b) suggests that the investment is for passive purposes, indicating a belief in the company's long-term value without immediate intentions to influence management or control.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

StockSavvy.ai notes that a significant stake taken by a specialized asset manager like Cormorant Asset Management, known for its focus on healthcare and life sciences, often signals a positive long-term view on the issuer's prospects within the biotechnology and immunotherapeutics sector. This could be interpreted by the market as a vote of confidence in MoonLake Immunotherapeutics' pipeline or strategic direction, potentially attracting further investor interest in a competitive industry.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake may increase confidence and potentially attract more investors, leading to positive share price movement.
• Management: The passive nature of the investment (Rule 13d-1(b)) suggests that management can continue executing its strategy without immediate pressure from this specific shareholder to change control or direction.

Key Dates

Recommendation

While the entry of a significant institutional investor like Cormorant Asset Management is a positive signal, this filing primarily discloses ownership and does not provide new operational or financial data to warrant a 'buy' or 'strong buy' recommendation. Investors should 'hold' and monitor MoonLake Immunotherapeutics for further developments, particularly regarding its clinical pipeline and financial performance, to assess the long-term implications of this institutional confidence.

Keywords

MoonLake Immunotherapeutics, Cormorant Asset Management, Bihua Chen, Schedule 13G, Beneficial Ownership, Class A ordinary shares, Institutional Investment, Biotechnology, Immunotherapeutics, Passive Investment